<DOC>
	<DOCNO>NCT00505453</DOCNO>
	<brief_summary>Vaccination currently effective mean control influenza prevent complication mortality person risk . Once year , meeting WHO expert take place , lead recommendation influenza A B strain use production vaccine come influenza season . This study design test safety/reactogenicity immunogenicity Fluviral Trivalent Split Virion Influenza Vaccine contain influenza strain recommend 2007-2008 season .</brief_summary>
	<brief_title>A Phase III , Open-Label , Single-Dose Study Evaluate Safety Immunogenicity Fluviral® Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy male female adult , 18 year age old . Female subject nonchildbearing potential . Written inform consent obtain subject . Acute disease time enrollment . Blood pressure abnormality . Any immunosuppressive condition , HIV cancer . Renal impairment , hepatic dysfunction , complicate insulindependent diabetes mellitus . Unstable cardiopulmonary disease require chronic medical therapy associate functional impairment . Any demyelinating disease , include GuillainBarré syndrome . Alcohol consumption and/or drug abuse . Receipt influenza vaccine within 9 month prior enrollment vaccine within 30 day prior enrollment . Any known suspected allergy Fluviral vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>